Skip to content
Peptide research

MOTS-c

Also known as Mitochondrial ORF of 12S rRNA type-c
Category
Longevity & Anti-Aging
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A mitochondria-derived peptide that activates AMPK signaling, marketed for metabolic health, fat loss, and exercise capacity. Its best-supported effects, better glucose handling and exercise capacity, come mostly from animal and mechanistic data; native MOTS-c has never been tested in a controlled human trial, so the human case is unproven. Most commercial supply is research-grade, with purity reported as low as 60 percent. Not approved in the US.

Read Full record

Studied uses & evidence

Studied uses(8)

  • Improved insulin sensitivity and glucose metabolism

    Medium

    Consistent animal data and an AMPK/GLUT4 mechanism; one small human analog trial showed lower glucose.

  • Reduced obesity and fat accumulation

    Low

    Strong animal weight and liver-fat data; the human analog trial showed no drug-versus-placebo benefit.

  • Enhanced physical performance and exercise capacity

    Medium

    Extensive animal data shows better running capacity; no human performance trial yet.

Evidence limits

Evidence Level
Preclinical

Over 95% of MOTS-c evidence comes from cell culture and animal (primarily mouse) studies. Human data consists of observational/correlational studies measuring endogenous MOTS-c levels, a few exercise intervention studies measuring MOTS-c as a biomarker (not administering it), and one Phase 1a/1b trial of the analog CB4211 enrolling 88 subjects: 65 healthy participants and 23 participants with obesity and NAFLD, of whom 20 completed the Phase 1b assessments. No human trials have directly tested native MOTS-c injection for any therapeutic purpose. The preclinical evidence is robust and consistent across multiple disease models, but clinical translation remains in very early stages.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Hypoglycemia-prone individuals

    Moderate

    MOTS-c enhances glucose uptake. May cause hypoglycemia in combination with insulin or sulfonylureas.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Native MOTS-c never given to humans in a controlled clinical trial

    High
  • Most commercial MOTS-c is research-grade (purity as low as 60%)

    High
  • Enhances glucose uptake; hypoglycemia risk with diabetes meds

    Moderate
  • Injection site reactions (CB4211 analog Phase 1)

    Low
  • Anecdotal palpitations and elevated heart rate

    Low
  • Nausea, bloating, mild diarrhea (user reports)

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.